Position in CRMD
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,291,379
-$1,280,341 QoQ
Shares Held
419,284
-37.7% QoQ
Ownership
0.538%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#25
of 194 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CRMD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026KENNEDY CAPITAL MANAGEMENT LLC holds $451,584,893 across 62 Biotechnology names. CRMD ranks #43 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
544,994 | $42,656,680 | |
| 2 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
193,215 | $21,452,661 | |
| 3 | NRIX |
Nurix Therapeutics, Inc.
|
724,508 | $17,576,564 | |
| 4 | CORT |
Corcept Therapeutics Inc
|
201,979 | $17,562,074 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
134,019 | $16,428,049 | |
| 6 | MGTX |
MeiraGTx Holdings plc
|
1,105,421 | $14,934,237 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
1,755,152 | $14,690,622 | |
| 8 | NAMS |
NewAmsterdam Pharma Co N.V.
|
421,374 | $14,280,364 |
All Filings in CRMD
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,291,379 | 419,284 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $4,571,720 | 673,302 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $7,653,761 | 658,105 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $7,659,901 | 658,633 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $5,915,792 | 480,178 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $2,490,062 | 404,231 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $3,063,768 | 378,243 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $3,069,947 | 379,944 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||